시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 만성 골수성 백혈병 치료 시장 보고서(2025년)
Chronic Myeloid Leukemia Treatment Global Market Report 2025
상품코드 : 1682059
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,242,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,023,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,803,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

만성 골수성 백혈병 치료 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 7.7%로 성장할 전망이며, 131억 2,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 효과적이고 인용성이 높은 치료에 대한 수요 증가, 헬스케어 지출 증가, 만성 골수성 백혈병 치료에 대한 투자, 개별화 의료 확대 등에 기인할 것으로 보입니다. 예측 기간 주요 동향에는 진단 및 스크리닝 개선, 만성 골수성 백혈병의 혁신적 치료, 표적 요법 개발, 첨단 조기 진단 및 스크리닝, 모니터링 기술이 포함됩니다.

골수성 백혈병 이환율의 상승은 향후 수년간 만성 골수성 백혈병(CML) 치료 시장의 확대를 견인할 것으로 보입니다. 골수성 백혈병은 골수에 발생하는 암의 일종으로 다양한 종류의 혈액세포를 생산하는 세포를 침범합니다. 만성 골수성 백혈병(CML) 치료의 주된 목적은 백혈병의 근본 원인에 대처함으로써 골수 기능을 강화하고, 궁극적으로는 혈구수 저하와 관련된 합병증의 위험을 낮추며, 화학요법 및 이식의 필요성을 줄여 골수성 백혈병 환자의 생존율을 개선하는 것입니다. 예를 들면, 2023년 1월, 미국의 임의 단체인 미국암협회(American Cancer Society)는, 2023년중에 성인 급성 골수성 백혈병(AML) 환자수는 약 20,380명, 사망자수는 약 11,310명으로 평가했습니다. 그 결과 골수성 백혈병 발생률 상승이 만성 골수성 백혈병(CML) 치료 시장 성장의 원동력이 되고 있습니다.

염색체 이상의 이환율의 상승은 향후 수년간 만성 골수성 백혈병(CML) 치료 시장 확대의 주요 촉진요인이 될 것으로 예상됩니다. 염색체 이상은 유전 정보의 중요한 담당자인 개인 염색체의 구조적 및 수치적 이상을 포함하고 있어 환자의 예후에 중대한 영향을 미치며, 특히 CML의 경우 보다 적극적인 치료가 필요할 수 있습니다. 예를 들면, 사우디아라비아에서 실시된 조사에 의하면, 선천 이상이 있는 신생아 59명 중 39.3%에서 염색체 이상이 인정되어, 신생아 집중 치료실(NICU) 입실자 전체의 2.3%를 차지했던 것이, 미국을 거점으로 하는 생물 의학 정보학과 계산 건강 데이터 과학 연구의 전문 기관인 국립 의학 도서관(NLM)의 보고로부터 밝혀졌습니다. 그 결과 염색체 이상 유병률 증가가 만성 골수성 백혈병(CML) 치료 시장의 확대를 견인하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Chronic myeloid leukemia (CML) constitutes a form of cancer that exerts its impact on the bone marrow and blood cells. It is characterized by the excessive production of abnormal white blood cells, referred to as granulocytes. The core objective of CML treatment is the management of the disease, alleviation of symptoms, and enhancement of the overall quality of life for patients grappling with this condition.

Treatment options in the domain of chronic myeloid leukemia encompass a range of approaches, including targeted therapy, chemotherapy, radiation therapy, splenectomy, and stem cell transplantation. Among these, targeted therapy assumes prominence as a cancer treatment modality focused on specific molecules or pathways integral to the growth and survival of cancer cells. The administration of these treatments can occur through diverse routes, including oral and parenteral methods, and caters to various end-users such as hospitals and specialized clinics, ultimately underscoring the comprehensive nature of CML management.

The chronic myeloid leukemia treatment market research report is one of a series of new reports from The Business Research Company that provides chronic myeloid leukemia treatment market statistics, including chronic myeloid leukemia treatment industry global market size, regional shares, competitors with a chronic myeloid leukemia treatment market share, detailed chronic myeloid leukemia treatment market segments, market trends and opportunities and any further data you may need to thrive in the chronic myeloid leukemia treatment industry. This chronic myeloid leukemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic myeloid leukemia treatment market size has grown strongly in recent years. It will grow from $9.2 billion in 2024 to $9.76 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising prevalence of chronic myeloid leukemia, growing awareness about cancer treatment, government initiatives, growing research and development activities for chronic myeloid leukemia treatments.

The chronic myeloid leukemia treatment market size is expected to see strong growth in the next few years. It will grow to $13.12 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to growing demand for effective and more tolerable treatments, rising healthcare spending, investments in chronic myeloid leukemia treatments, growing personalized medicine. Major trends in the forecast period include improved diagnosis and screening, innovative treatments for chronic myeloid leukemia, development of targeted therapies, advanced early diagnosis and screening, monitoring technologies.

The rising incidence of myeloid leukemia is poised to drive the expansion of the chronic myeloid leukemia (CML) treatment market in the coming years. Myeloid leukemia, a form of cancer originating in the bone marrow, affects the cells responsible for producing various blood cell types. The primary objective of chronic myeloid leukemia (CML) treatment is to enhance bone marrow function by addressing the root cause of leukemia, ultimately lowering the risk of complications related to low blood cell counts, reducing the necessity for chemotherapy and transplants, and improving survival rates among individuals with myeloid leukemia. For instance, in January 2023, the American Cancer Society, a US-based voluntary health organization, estimated that there were approximately 20,380 cases and 11,310 deaths from acute myeloid leukemia (AML) in adults during the year 2023. Consequently, the escalating incidence of myeloid leukemia serves as a driving force behind the chronic myeloid leukemia (CML) treatment market's growth.

The rising incidence of chromosome abnormalities is expected to be a key driver behind the expansion of the chronic myeloid leukemia (CML) treatment market in the coming years. Chromosome abnormalities, which encompass structural or numerical irregularities in an individual's chromosomes-critical carriers of genetic information, have a significant impact on patients' prognoses and may necessitate more aggressive treatments, particularly in cases of CML. For instance, based on a study conducted in Saudi Arabia, it was revealed that chromosome abnormalities were present in 39.3% of 59 newborn infants with congenital anomalies, accounting for 2.3% of total neonatal intensive care unit (NICU) admissions, as reported by the National Library of Medicine (NLM), a US-based institution specializing in biomedical informatics and computational health data science research. Consequently, the increasing prevalence of chromosome abnormalities is driving the expansion of the chronic myeloid leukemia (CML) treatment market.

Prominent companies in the chronic myeloid leukemia (CML) treatment market prioritize the development of groundbreaking diagnostic products to maintain their market presence. An illustrative instance of such innovation is found in the actions of Precipio, Inc., a US-based diagnostic company specializing in cancer diagnostics. For instance, in August 2023, Precipio, Inc. introduced the BCR-ABL 2.0 Panel, specifically designed for chronic myeloid leukemia (CML) diagnosis. This advanced panel plays a pivotal role in identifying the BCR-ABL1 gene, which is crucial for diagnosing CML. It stands out as the most sophisticated BCR-ABL panel, distinguished by its comprehensive coverage, streamlined workflow, reduced costs, and the enhanced quality of patient care. Notably, it includes the detection of ABL1 mutations, eliminating the necessity for a secondary round of testing for the BCR-ABL1 gene and providing highly accurate results. This remarkable innovation significantly shapes the landscape of chronic myeloid leukemia (CML) treatment.

In November 2022, Merck & Co. Inc., a US-based multinational pharmaceutical company, acquired Imago BioSciences for $1.35 billion. This acquisition enhances Merck's ability to develop cutting-edge therapies for hematologic malignancies, positioning the company to address unmet medical needs in cancer treatment, foster growth in a competitive market, and improve patient care. Imago BioSciences Inc., a US-based clinical-stage biopharmaceutical company, specializes in developing innovative treatments for myeloproliferative neoplasms and other bone marrow diseases, including chronic myelogenous leukemia, polycythemia vera, and essential thrombocythemia.

Major companies operating in the chronic myeloid leukemia treatment market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Merck and Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Otsuka Holdings Co Ltd., Mylan N.V., Astellas Pharma Inc., Incyte Corporation, Lupin Limited, Seattle Genetics Inc., Innovent Biologics Inc., Xencor Inc., ARIAD Pharmaceuticals Inc., Celon Laboratories Pvt. Ltd.

North America was the largest region in the chronic myeloid leukemia treatment market in 2024. The regions covered in chronic myeloid leukemia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic myeloid leukemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic myeloid leukemia treatment market consists of revenues earned by entities by providing diagnosis and staging, medical consultations and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic myeloid leukemia (CML) market also includes sales of imatinib, dasatinib, bosutinib and ponatinib. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Myeloid Leukemia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic myeloid leukemia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for chronic myeloid leukemia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic myeloid leukemia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Chronic Myeloid Leukemia Treatment Market Characteristics

3. Chronic Myeloid Leukemia Treatment Market Trends And Strategies

4. Chronic Myeloid Leukemia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Chronic Myeloid Leukemia Treatment Growth Analysis And Strategic Analysis Framework

6. Chronic Myeloid Leukemia Treatment Market Segmentation

7. Chronic Myeloid Leukemia Treatment Market Regional And Country Analysis

8. Asia-Pacific Chronic Myeloid Leukemia Treatment Market

9. China Chronic Myeloid Leukemia Treatment Market

10. India Chronic Myeloid Leukemia Treatment Market

11. Japan Chronic Myeloid Leukemia Treatment Market

12. Australia Chronic Myeloid Leukemia Treatment Market

13. Indonesia Chronic Myeloid Leukemia Treatment Market

14. South Korea Chronic Myeloid Leukemia Treatment Market

15. Western Europe Chronic Myeloid Leukemia Treatment Market

16. UK Chronic Myeloid Leukemia Treatment Market

17. Germany Chronic Myeloid Leukemia Treatment Market

18. France Chronic Myeloid Leukemia Treatment Market

19. Italy Chronic Myeloid Leukemia Treatment Market

20. Spain Chronic Myeloid Leukemia Treatment Market

21. Eastern Europe Chronic Myeloid Leukemia Treatment Market

22. Russia Chronic Myeloid Leukemia Treatment Market

23. North America Chronic Myeloid Leukemia Treatment Market

24. USA Chronic Myeloid Leukemia Treatment Market

25. Canada Chronic Myeloid Leukemia Treatment Market

26. South America Chronic Myeloid Leukemia Treatment Market

27. Brazil Chronic Myeloid Leukemia Treatment Market

28. Middle East Chronic Myeloid Leukemia Treatment Market

29. Africa Chronic Myeloid Leukemia Treatment Market

30. Chronic Myeloid Leukemia Treatment Market Competitive Landscape And Company Profiles

31. Chronic Myeloid Leukemia Treatment Market Other Major And Innovative Companies

32. Global Chronic Myeloid Leukemia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Myeloid Leukemia Treatment Market

34. Recent Developments In The Chronic Myeloid Leukemia Treatment Market

35. Chronic Myeloid Leukemia Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기